LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the "Class Period†). Telix investors have until January 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS. ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for securities fraud, alleging that the company made materially false statements and failed to disclose adverse facts about its business and operations during the class period from February 21, 2025, to August 28, 2025 [1][5]. Summary by Sections Company Disclosures - On July 22, 2025, Telix disclosed it received a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [4]. Allegations in the Lawsuit - The lawsuit alleges that throughout the class period, Telix's management made materially false and misleading statements and failed to disclose critical adverse facts, including: 1. Overstating the progress made on prostate cancer therapeutic candidates [5]. 2. Overstating the quality of Telix's supply chain and partners [5]. 3. Positive statements about the company's business and prospects were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - A securities class action has been filed against Telix Pharmaceuticals Ltd. for alleged violations of the Securities Exchange Act of 1934, with a class period from February 21, 2025, to August 28, 2025, and investors have until January 9, 2026, to seek appointment as lead plaintiff [1]. Allegations - The lawsuit alleges that Telix and its executives overstated progress on the company's prostate cancer therapeutic candidates [6]. - The company is also accused of overstating the quality of its supply chain and partner operations [6]. Key Events - On February 20, 2025, Telix held an earnings call where executives claimed significant progress in their therapeutic pipeline, particularly in prostate cancer, which was said to be in Phase 3 [6]. - On July 22, 2025, Telix reported to the SEC that it received a subpoena regarding its prostate cancer therapeutic candidates, leading to a 16% drop in share price, the largest decline in 21 months [6]. - Following the subpoena news, Telix ADSs fell by $1.70 (10.4%) to close at $14.58 on July 23, 2025, and further dropped by $0.69 (4.7%) to close at $13.89 on July 24, 2025 [6]. - On August 28, 2025, Telix announced that the FDA issued a Complete Response Letter for its renal cancer drug candidate, resulting in a $1.95 (16.1%) drop in share price to close at $10.15 [6]. - The following day, Telix ADSs fell an additional $0.60 (5.9%) to close at $9.55 on August 29, 2025 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [2][5]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates [5]. - It is claimed that Telix materially overstated the quality of its supply chain and partners, leading to misleading statements about its business and operations [5]. - The lawsuit asserts that when the true details emerged, investors suffered damages, particularly following significant announcements from the company [5]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of its American Depositary Shares to drop over 13% in two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in its Chemistry, Manufacturing, and Controls package, leading to a further decline of over 21% in its ADS price [7]. Group 3: Legal Proceedings and Investor Participation - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Telix is January 9, 2026 [2]. - The lead plaintiff is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Faruqi & Faruqi encourages anyone with information regarding Telix's conduct to come forward, including whistleblowers and former employees [9].

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 12, 2025 3:12 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between Fe ...

Core Viewpoint - Telix Pharmaceuticals Limited is facing a securities class action lawsuit following significant stock declines due to a regulatory subpoena and an FDA rejection letter [1] Group 1: Legal Proceedings - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., seeks to represent investors who acquired Telix securities between February 21, 2025, and August 28, 2025 [3] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][8] Group 2: Company Statements and Allegations - The litigation focuses on Telix's statements regarding its prostate cancer therapeutic candidates TLX591 and TLX592, as well as its kidney cancer detection candidate Zircaix [4] - During the class period, Telix claimed progress in its therapeutic pipeline and emphasized its global manufacturing capabilities as a competitive advantage [5] - The lawsuit alleges that Telix made false and misleading statements, overstating the progress of its prostate cancer candidates and the quality of its supply chain [5] Group 3: Regulatory Issues - On July 22, 2025, Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates, leading to a sharp decline in stock price [6] - On August 28, 2025, Telix received a Complete Response Letter from the FDA for its Zircaix BLA, citing deficiencies in manufacturing and requesting additional data [7]

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Januar ...

ATLANTA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (“Telix”) (NASDAQ: TLX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Telix’s business, operations, and prospects, including allegations that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants ...

Core Viewpoint - Telix Pharmaceuticals Limited is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1: Company Overview - Telix Pharmaceuticals Limited is currently involved in legal proceedings related to securities law violations, indicating potential governance and compliance issues [1] Group 2: Legal Implications - The lawsuit suggests that there may be significant legal risks associated with Telix Pharmaceuticals, which could affect its market performance and investor relations [1]

NEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia ...